Abstract LB-216: CSLEX (sialyl LewisX) is an important and useful tumor marker in monitoring breast cancer patients

Abstract

Background: CSLEX-1 is one of the monoclonal antibodies for which the structure of the antigen is known. This antigen is called CSLEX (Sialyl Le X). It has been reported that CSLEX may be more useful than CEA in combination with CA15-3 in monitoring breast cancer patients.

Methods: We measured and evaluated the serum levels of some tumor markers, including CSLEX, in a total of 482 breast cancer patients with or without metastasis who consecutively visited the outpatient clinic of the Division of Breast and Endocrine Surgery, Shinshu University Hospital, between April 2007 and September 2007.

Results: All serum levels of tumor markers in a single measurement correlated significantly with the status of metastasis (P < 0.01). All combinations of combined measurements, such as CEA and CA15-3, CEA and NCC-ST439, CEA and CSLEX, CA15-3 and NCC-ST439, and CA15-3 and CSLEX, also correlated significantly with the status of metastasis (P < 0.01). The sensitivity, specificity, positive-predictive value, negative-predictive value and accuracy were almost the same between CSLEX and NCC-ST439, which belongs to the type II carbohydrate antigens. The cut-off values of serum CSLEX and NCC-ST439 were 38.8 ± 52.7 U/ml and 22.1 ± 27.8 U/ml, respectively (P = 0.16). Conclusions: These data support there are no differences between CSLEX and NCC-ST439 as diagnostic parameters in single or combined measurements. The cut-off value of serum CSLEX tended to be higher compared with that of NCC-ST439.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-216.